Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | £379 | £176 | £7 | £13,343 |
| - Cash | £13 | £13 | £15 | £21 |
| + Debt | £60 | £31 | £36 | £11 |
| Enterprise Value | £426 | £194 | £28 | £13,333 |
| Revenue | £55 | £55 | £60 | £73 |
| % Growth | -0.3% | -7.4% | -18.1% | – |
| Gross Profit | £25 | £30 | £33 | £49 |
| % Margin | 45.7% | 53.9% | 54.9% | 67.3% |
| EBITDA | -£29 | -£31 | -£36 | -£9 |
| % Margin | -53.5% | -55.7% | -60.8% | -11.9% |
| Net Income | -£40 | -£40 | -£43 | -£14 |
| % Margin | -72.9% | -72.9% | -72.3% | -18.9% |
| EPS Diluted | -0.008 | -0.011 | -0.064 | -0.021 |
| % Growth | 21.5% | 83.4% | -200.5% | – |
| Operating Cash Flow | -£29 | -£32 | -£31 | -£14 |
| Capital Expenditures | -£3 | -£3 | -£5 | -£3 |
| Free Cash Flow | -£32 | -£36 | -£36 | -£17 |